PL4346818T3 - Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid - Google Patents
Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamidInfo
- Publication number
- PL4346818T3 PL4346818T3 PL22741050.3T PL22741050T PL4346818T3 PL 4346818 T3 PL4346818 T3 PL 4346818T3 PL 22741050 T PL22741050 T PL 22741050T PL 4346818 T3 PL4346818 T3 PL 4346818T3
- Authority
- PL
- Poland
- Prior art keywords
- difluoro
- carboxamide
- trifluoromethyl
- carbonyl
- pyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196933P | 2021-06-04 | 2021-06-04 | |
| US202163196937P | 2021-06-04 | 2021-06-04 | |
| US202163285197P | 2021-12-02 | 2021-12-02 | |
| US202163285201P | 2021-12-02 | 2021-12-02 | |
| PCT/US2022/032253 WO2022256708A1 (en) | 2021-06-04 | 2022-06-03 | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4346818T3 true PL4346818T3 (pl) | 2026-03-23 |
Family
ID=82492526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22741050.3T PL4346818T3 (pl) | 2021-06-04 | 2022-06-03 | Stałe postacie dawkowania i schematy dawkowania obejmujące (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metoksyfenylo)-4,5-dimetylo-5- (trifluorometylo)tetrahydrofurano-2-karbonylo]amino]pirydyno-2- karboksyamid |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240285596A1 (pl) |
| EP (2) | EP4346818B1 (pl) |
| JP (1) | JP2024520649A (pl) |
| KR (1) | KR20240031299A (pl) |
| AU (1) | AU2022284952A1 (pl) |
| BR (1) | BR112023025264A2 (pl) |
| CA (1) | CA3222197A1 (pl) |
| DK (1) | DK4346818T3 (pl) |
| ES (1) | ES3063352T3 (pl) |
| FI (1) | FI4346818T3 (pl) |
| HR (1) | HRP20260068T1 (pl) |
| IL (1) | IL308954A (pl) |
| LT (1) | LT4346818T (pl) |
| MA (1) | MA64856B1 (pl) |
| MD (1) | MD4346818T2 (pl) |
| MX (1) | MX2023014376A (pl) |
| PL (1) | PL4346818T3 (pl) |
| PT (1) | PT4346818T (pl) |
| RS (1) | RS67745B1 (pl) |
| SI (1) | SI4346818T1 (pl) |
| SM (1) | SMT202600064T1 (pl) |
| TW (1) | TW202317108A (pl) |
| WO (1) | WO2022256708A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| IL321882A (en) * | 2023-01-06 | 2025-09-01 | Haisco Pharmaceutical Group Co Ltd | The origin of tetrahydrothiophene and its use in medicine |
| US20250186419A1 (en) * | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| CN120058684A (zh) * | 2024-02-23 | 2025-05-30 | 山东盛迪医药有限公司 | 一种取代四氢呋喃化合物的结晶形式及其制备方法 |
| CN120058686A (zh) * | 2024-02-23 | 2025-05-30 | 山东盛迪医药有限公司 | 一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途 |
| CN117838648B (zh) * | 2024-03-05 | 2024-05-28 | 瑞阳制药股份有限公司 | Suzetrigine片剂及其制备方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
| WO2026012382A1 (zh) * | 2024-07-10 | 2026-01-15 | 海思科医药集团股份有限公司 | 一种硫杂环戊基衍生物的药物制剂及其在医药上的应用 |
| CN119143737B (zh) * | 2024-11-18 | 2025-07-18 | 嘉兴安帝康生物科技有限公司 | 四氢呋喃甲酰胺类钠通道调节剂及其在医药上的应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| ATE342504T1 (de) | 2000-07-10 | 2006-11-15 | Vertex Pharma San Diego Llc | Ionenkanal-testverfahren |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6492618B1 (en) | 2000-11-02 | 2002-12-10 | Tri Tool Inc. | Automatic weld head alignment and guidance system and method |
| AP2007003887A0 (en) | 2004-07-23 | 2007-02-28 | Pfizer | Pyridine derivatives |
| AR063280A1 (es) | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| KR20100007956A (ko) | 2007-05-03 | 2010-01-22 | 화이자 리미티드 | 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체 |
| KR101663336B1 (ko) | 2008-12-26 | 2016-10-06 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규한 바이시클릭 헤테로고리 화합물 |
| US9174999B2 (en) | 2009-05-07 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US8629149B2 (en) | 2009-09-04 | 2014-01-14 | Zalicus Pharmaceuticals Ltd. | Oxopiperazine derivatives for the treatment of pain and epilepsy |
| CA2812526A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| BR112013019211A2 (pt) | 2011-02-02 | 2021-07-06 | Vertex Pharma | amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon |
| CN103443105A (zh) | 2011-02-18 | 2013-12-11 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的苯并二氢吡喃-螺环哌啶酰胺 |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| MD20140037A2 (ro) | 2011-10-26 | 2014-08-31 | Pfizer Limited | Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| MX2014008591A (es) | 2012-01-16 | 2014-08-22 | Vertex Pharma | Piperidinamidas piranoespirociclicas como moduladores de canales de iones. |
| CA2861439C (en) | 2012-02-03 | 2016-07-12 | Pfizer Inc. | Benzimidazole and imidazopyridine derivatives as sodium channel modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| AR094668A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Amidas como moduladores de canales de sodio |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| PE20160548A1 (es) | 2013-07-19 | 2016-05-21 | Vertex Pharma | Sulfonamidas como moduladores de canales de sodio |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| WO2015157559A2 (en) | 2014-04-09 | 2015-10-15 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins for the treatment of pain |
| SG11201707000UA (en) | 2015-03-02 | 2017-09-28 | Amgen Inc | Bicyclic ketone sulfonamide compounds |
| US10112953B2 (en) | 2015-09-30 | 2018-10-30 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| EP3601290B1 (en) | 2017-03-29 | 2021-11-24 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| CN110831945B (zh) | 2017-03-29 | 2023-08-08 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| CA3069720A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| SG11202001129VA (en) * | 2017-08-11 | 2020-03-30 | Merck Patent Gmbh | Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| SG11202100137TA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
| WO2020072835A1 (en) | 2018-10-03 | 2020-04-09 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| KR102860523B1 (ko) | 2018-11-02 | 2025-09-16 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드 |
| US12344595B2 (en) | 2018-11-02 | 2025-07-01 | Merck Sharp & Dohme Llc | 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors |
| BR112021012909A2 (pt) | 2019-01-04 | 2021-09-14 | Jiangsu Hengrui Medicine Co., Ltd. | Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112996774B (zh) | 2019-01-25 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用 |
| US20230103791A1 (en) | 2019-06-27 | 2023-04-06 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
| CN112300051A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN112300069A (zh) | 2019-07-31 | 2021-02-02 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| CN112390745B (zh) | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2021032074A1 (zh) | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
| CN112441969A (zh) | 2019-08-30 | 2021-03-05 | 明慧医药（上海）有限公司 | 一种选择性钠通道调节剂及其制备和应用 |
| TWI770607B (zh) | 2019-09-12 | 2022-07-11 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物及其製備方法和用途 |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| CN111217776A (zh) | 2020-01-19 | 2020-06-02 | 中国人民解放军军事科学院军事医学研究院 | 含苯并杂环结构的酰胺衍生物、组合物和应用 |
| JP2021195367A (ja) | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| ES3023366T3 (en) | 2020-06-10 | 2025-05-30 | Amgen Inc | Heteroalkyl dihydroquinoline sulfonamide compounds |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| JP7323723B2 (ja) | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド |
| EP4167994A4 (en) | 2020-06-17 | 2024-07-24 | Merck Sharp & Dohme LLC | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS |
| BR112022024476A2 (pt) | 2020-06-17 | 2022-12-27 | Merck Sharp & Dohme Llc | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 |
| CN116368139A (zh) | 2020-08-14 | 2023-06-30 | 赛特温治疗公司 | 用于治疗疼痛的nav1.7的非水合酮类抑制剂 |
| TW202214259A (zh) | 2020-08-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種選擇性ＮａＶ抑制劑的前藥及其晶型 |
| TW202220962A (zh) | 2020-08-19 | 2022-06-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 選擇性NaV抑制劑的結晶形式及其製備方法 |
| CN111808019B (zh) | 2020-09-08 | 2020-11-27 | 上海济煜医药科技有限公司 | 一种并环化合物及其应用 |
| CN112225695B (zh) | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
| CN112457294B (zh) | 2021-01-27 | 2021-06-04 | 上海济煜医药科技有限公司 | 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途 |
-
2022
- 2022-06-03 KR KR1020247000227A patent/KR20240031299A/ko active Pending
- 2022-06-03 US US18/566,176 patent/US20240285596A1/en active Pending
- 2022-06-03 ES ES22741050T patent/ES3063352T3/es active Active
- 2022-06-03 MA MA64856A patent/MA64856B1/fr unknown
- 2022-06-03 RS RS20260118A patent/RS67745B1/sr unknown
- 2022-06-03 BR BR112023025264A patent/BR112023025264A2/pt unknown
- 2022-06-03 DK DK22741050.3T patent/DK4346818T3/da active
- 2022-06-03 MX MX2023014376A patent/MX2023014376A/es unknown
- 2022-06-03 MD MDE20240382T patent/MD4346818T2/ro unknown
- 2022-06-03 WO PCT/US2022/032253 patent/WO2022256708A1/en not_active Ceased
- 2022-06-03 AU AU2022284952A patent/AU2022284952A1/en active Pending
- 2022-06-03 PT PT227410503T patent/PT4346818T/pt unknown
- 2022-06-03 SM SM20260064T patent/SMT202600064T1/it unknown
- 2022-06-03 SI SI202230236T patent/SI4346818T1/sl unknown
- 2022-06-03 CA CA3222197A patent/CA3222197A1/en active Pending
- 2022-06-03 IL IL308954A patent/IL308954A/en unknown
- 2022-06-03 HR HRP20260068TT patent/HRP20260068T1/hr unknown
- 2022-06-03 JP JP2023574381A patent/JP2024520649A/ja active Pending
- 2022-06-03 FI FIEP22741050.3T patent/FI4346818T3/fi active
- 2022-06-03 LT LTEPPCT/US2022/032253T patent/LT4346818T/lt unknown
- 2022-06-03 EP EP22741050.3A patent/EP4346818B1/en active Active
- 2022-06-03 PL PL22741050.3T patent/PL4346818T3/pl unknown
- 2022-06-03 EP EP25220063.9A patent/EP4714435A2/en active Pending
- 2022-06-06 TW TW111120909A patent/TW202317108A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI4346818T3 (fi) | 2026-02-05 |
| EP4346818B1 (en) | 2025-12-03 |
| ES3063352T3 (en) | 2026-04-16 |
| HRP20260068T1 (hr) | 2026-02-27 |
| BR112023025264A2 (pt) | 2024-02-20 |
| LT4346818T (lt) | 2026-03-25 |
| MX2023014376A (es) | 2024-03-04 |
| SMT202600064T1 (it) | 2026-03-09 |
| AU2022284952A1 (en) | 2023-12-14 |
| SI4346818T1 (sl) | 2026-03-31 |
| DK4346818T3 (da) | 2026-02-02 |
| PT4346818T (pt) | 2026-02-17 |
| CA3222197A1 (en) | 2022-12-08 |
| RS67745B1 (sr) | 2026-03-31 |
| EP4346818A1 (en) | 2024-04-10 |
| MA64856B1 (fr) | 2026-02-27 |
| MD4346818T2 (ro) | 2026-03-31 |
| IL308954A (en) | 2024-01-01 |
| EP4714435A2 (en) | 2026-03-25 |
| WO2022256708A1 (en) | 2022-12-08 |
| KR20240031299A (ko) | 2024-03-07 |
| US20240285596A1 (en) | 2024-08-29 |
| TW202317108A (zh) | 2023-05-01 |
| JP2024520649A (ja) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202600064T1 (it) | Forme farmaceutiche solide e regimi di dosaggio comprendenti (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-metossi-fenil)-4,5-dimetil-5-(trifluorometil) tetraidrofuran-2-carbonil]ammino]piridin-2-carbossammide | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| EA200501586A1 (ru) | Фармацевтические продукты | |
| DE602004030344D1 (de) | Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen | |
| SE0003449L (sv) | Cancerhämmande kompositioner | |
| IL212419A (en) | Use of an isolated human antibody tnfa antibody to create a cure for a disease that is rheumatoid arthritis or autoimmune ovaitis, a pharmacological drug, kit and pre-loaded syringe containing it | |
| EP2277867A3 (en) | Compounds, pharmaceutical compositions thereof and their use in treating cancer | |
| BG105189A (bg) | Капсула от две части за пълнене с фармацевтични препарати за прахови инхалатори | |
| EA200401252A1 (ru) | Микрочастицы лекарственных веществ | |
| BR0313627A (pt) | Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores | |
| IL174301A0 (en) | Pharmaceutical formulations, methods and dosing regimens for the treatment and prevention of acute coronary syndromes | |
| EE200200622A (et) | Aromataasi inhibiitori kasutamine farmatseutilisekompositsiooni valmistamiseks, mis on ette nähtudHER2 valgu liigse avaldumisega hormoon-sõltuva häire raviks, ja meetod vähivastase ravi kõrvaltoimete vähendamiseks | |
| WO2005070965A3 (en) | Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases | |
| HK40109212A (en) | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide | |
| Fenichel et al. | Combination products as first-line pharmacotherapy | |
| EP4324841A4 (en) | Cell-penetrating peptide, anticancer peptide and pharmaceutical composition for preventing or treating cancer therewith | |
| EP4180446A4 (en) | CYCLIC PEPTIDE, PEPTIDE COMPLEX AND MEDICINAL COMPOSITION CONTAINING THE CYCLIC PEPTIDE AND/OR THE PEPTIDE COMPLEX | |
| FR2865208B1 (fr) | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique | |
| EP4070808A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BEHCET'S DISEASE AND RHEUMATOID ARTHRITIS, HAVING A PEPTIDE OR MIXTURE THEREOF AS THE ACTIVE INGREDIENT | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| AU2024248738A1 (en) | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide | |
| EP1854798A3 (en) | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | |
| WO2006121857A3 (en) | Unsolvated and host-guest solvated crystalline forms of (2e,4s)-4-[(n-{[(2r)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-l-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses | |
| AU2024396473A1 (en) | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same | |
| CA3279434A1 (en) | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |